Stephens & Co. Reiterates Equal-Weight on Lifecore Biomedical, Maintains $6 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Stephens & Co. analyst Jacob Johnson reiterates Lifecore Biomedical (NASDAQ:LFCR) with a Equal-Weight and maintains $6 price target.
Stephens & Co. analyst Jacob Johnson reiterates Lifecore Biomedical (NASDAQ:LFCR) with a Equal-Weight and maintains $6 price target.